News
WHIPPANY, NJ, USA I April 29, 2025 I Bayer announced today initiation of a Phase I clinical trial with 225Ac-GPC3 (BAY 3547926), an investigational targeted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback